OCGN - Ocugen, Inc. Debt to Book Capitalization Ratio

Ocugen, Inc. (OCGN) generates revenue through the sale of gene therapies for vision loss and the development of immune vaccines. The business relies on proprietary clinical protocols and unique modifiers that retain research centers. This chart of stock quotes on the GURU.Markets platform, where the indicator equals 0.00, demonstrates the capital burn stage of a startup that covers cell therapy costs through regular equity offerings.

This indicator measures the proportion of borrowed funds relative to equity, determining the degree of financial leverage and the risk of credit default. By analyzing levels of financial dependence based on balance sheet capital, an investor assesses the aggressiveness of the expansion of Ocugen, Inc. (OCGN), whose development strategy is constrained by basic environmental regulations and minimum operating costs for laboratory waste disposal.